Indole-3-carbinol (I3C), a naturally occurring compound in vegetables such as cabbage, broccoli and Brussel's sprouts, and its dimerization product 3-3'-diindolylmethane (DIM) are promising chemotherapeutic and chemopreventative agents for human reproductive cancers. We have demonstrated that the direct exposure of human breast cancer cells to I3C or DIM induces a stringent G1 cell cycle arrest through a multistep signaling cascade that controls expression, activity and cellular utilization of key cell cycle components. I3C, but not DIM, down-regulates cyclin dependent kinase-6 (CDK6) expression and promoter activity, whereas, DIM selectively and rapidly stimulates expression and promoter activity of p21Waf1/Cip1, a critical inhibitor of certain CDKs. The indole regulation of cell cycle gene expression result from specific changes in Sp1 transcription factor-promoter interactions. We have recently discovered that I3C, but not DIM, alters the size, composition and subcellular localization (nuclear to cytoplasm) of the CDK2 protein complex, and a novel 85 kDa protein was uncovered that associates with the CDK2 protein complex in an I3C dependent manner. Thus, the transcriptional control of CDK6 and p21Waf1/Cip1, and the posttanslational regulation of CDK2 protein complex utilization are newly defined down-stream targets of the anti-proliferative indole signaling pathway in human breast cancer cells. Our hypothesis is that I3C and DIM induce a G1 cell cycle arrest of human reproductive cancer cells by activating complementary and distinct cascades that that subsequently control the transcription and posttranslational utilization of key cell cycle components. The indole regulated transcription factors, in addition to Spl, that target the CDK6 and p21Waf1/Cip1 promoters will be identified by interactions with indole responsive regions of cell cycle gene promoters, and functionally tested in a cellular text by manipulation of their expression and/or activity. The novel 85 kDa protein that interacts with the CDK2 protein complex in an I3C dependent manner will be defined and characterized for its role in the I3C disruption of the CDK2 protein complex. The actions of the I3C regulated cell cycle components on cancer cell invasion properties, and in the formation of human breast cancer cell-derived tumors will be assessed using in vitro and in vivo strategies. Our collaborative studies represent the first experimental steps necessary to understand the transcriptional and posttranslational mechanisms by which natural indoles control the cell cycle of human breast cancer cells. This information will be particularly valuable to develop new classes of I3C-based therapeutics for reproductive cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102360-05
Application #
7431577
Study Section
Chemo/Dietary Prevention Study Section (CDP)
Program Officer
Kim, Young S
Project Start
2004-07-30
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2011-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$257,229
Indirect Cost
Name
University of California Berkeley
Department
Internal Medicine/Medicine
Type
Schools of Arts and Sciences
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Hargraves, Kris G; He, Lin; Firestone, Gary L (2016) Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol Carcinog 55:486-98
Tin, Antony S; Park, Anna H; Sundar, Shyam N et al. (2014) Essential role of the cancer stem/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells. BMC Biol 12:72
Aronchik, Ida; Kundu, Aishwarya; Quirit, Jeanne G et al. (2014) The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation. Mol Cancer Res 12:1621-1634
Tran, Kalvin Q; Tin, Antony S; Firestone, Gary L (2014) Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-?B transcriptional signaling. Anticancer Drugs 25:270-81
Aronchik, Ida; Chen, Tony; Durkin, Kathleen A et al. (2012) Target protein interactions of indole-3-carbinol and the highly potent derivative 1-benzyl-I3C with the C-terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling. Mol Carcinog 51:881-94
Marconett, Crystal N; Singhal, Ankur K; Sundar, Shyam N et al. (2012) Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol Cell Endocrinol 363:74-84
Marconett, Crystal N; Sundar, Shyam N; Tseng, Min et al. (2011) Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis 32:1315-23
Aronchik, Ida; Bjeldanes, Leonard F; Firestone, Gary L (2010) Direct inhibition of elastase activity by indole-3-carbinol triggers a CD40-TRAF regulatory cascade that disrupts NF-kappaB transcriptional activity in human breast cancer cells. Cancer Res 70:4961-71
Marconett, Crystal N; Morgenstern, Travis J; San Roman, Adrianna K et al. (2010) BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther 10:397-405
Marconett, Crystal N; Sundar, Shyam N; Poindexter, Kevin M et al. (2010) Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop. Mol Biol Cell 21:1166-77

Showing the most recent 10 out of 30 publications